JUST DAIL ANOTHER GEM OF A MULTIBAGGER STOCK FROM TRENDZOFMARKET

JUST DIAL RECOMMENDED TO CLIENTS ON DEC 8 TH TO BUY STOCK AT 1145  JUST 12 DAYS STOCK MOVED WHOPPING 24%  HIT 1336 ALMOST 300 RS GIAN IN JUST 2 WEEKS TIME

THINK WISELY WEATHER TO JOIN US FOR THESE TYPE OF INVESTMENT AND SHORT TERM CALLS

THIS WAS OUR AMIL TO CLIENTS ON  DEC 8

s Just Dial going to do what Jubilant Foodworks stock did to investors? Well, the early signs do suggest that.

Jubilant Foodworks started its bullish journey post IPO from Rs. 200 to Rs. 360 in 3 months and then it pulled back to Rs. 260 in next 1.5 months. Lots of folks were confused on future direction of the stock. The stock after minor pullback took off from Rs. 260 and never looked back. 3.5 years later – today stock is at Rs. 1340. It turned out to be 5x mover.
Here’s the Just Dial Chart 

Just Dial has taken off in a big way post IPO. From levels of 600 – stock has moved to 1400 in less than 6 months. Now, stock has pulled back to 50 dma and it seems like an excellent place to enter before stock takes another upmove. Just Dial can be many year story and one needs to exhibit tremendous patience to fully benefit from it.
ITS A PURE INVESTMENT STOCK FOR MULTI BAGGER GAINS

We are adding the stock to Breakout and Leadership set.

2 NIFTY HEAVY WEIGHT TRIANGLE; BREAK DOWN

1. BID DADDY OF INDIAN STOCK MARKET : RELIANCE 

CALL STILL NOT GET ACTIVATED 

 

SELL  RELAINCE  BELOW 840 LOT SIZE 250 

2. BIG BANKING MAJOR  HDFC

BUY HDFC   780 PE @ 7.50 TGT 17-25 LOT SIZE 250

SELL HDFC @ 795 SL 805 ON CLOSING BASIS TGT 770-750

INFOSYS SAFE BET FOR 2014

SAFE STOCK OF 2013 INFOSYS
STOCK HIT FRESH ALL TIME HIGH  3670 STILL LOOK  TO SET VERY STRONG GAINS IN 2014 

MY UPDATE ON DEC 19

STOCK WAS TRADING AT 3300 LEVELS WHEN THE MAIL WAS SEND ON NOV 27  2013
TODAY THE STOCK  HIT FRESH ALL TIME HIGH 3544.. STILL STOCK IS ONE OF THE SAFEST BEST AND LONG LONG WAY TO GO FORWARD ITS A PURE INVESTMENT CALL WHICH GIVE IMMENSE RETURNS IN COMING  MONTHS TO COME

THIS WAS THE MAIL SEND ON NOV 19 TH 2013
INFOSYS SAFE BET FOR 2014


Last few years have not been great for Infosys investors. But it appears this is about to change in 2014. Infosys stock seems set for considerable gains. Here’s why

Infosys stock has broken out on weekly chart above 3000 and the breakout structure seems robust for huge follow through gains. The only issue: patience.

Here’s the Breakout on weekly chart

 

As you can see in the weekly chart above, Infosys was struggling below 2995 for years. But that seems to have changed post its breakout above 2995. The breakout happened in August and, even when, many months have passed, stock has not done much. The consolidation appears healthy and does set the stock for huge gains over next 12 months.
What should one do?
Keep Buying the stock between 3000 and 3300 on regular basis and build position for huge gains in next 12 months. As always, there is no certainty in market and if things turn for worse and Infosys stock slips below 50 week ma, then exit and wait for technical to improve.

CIPLA A MUST BUY FOR PULL BACK TRADE

 RECOMMENDED TO BUY CIPLA FOR A PULL BACK TRADE

BUY CIPLA @ 375 LOT SIZE 500 SL 360  HIT 396 NOW PROFIT 10000 RS

NOW LONG TERM HOLDERS CAN HAVE A DEEP LOOK IN TO THE STOCK

OUR MAIL TO PAID CLIENTS ON 16 TH DEC

Cipla broke out above 360 to New HIGH in August 2012 and 1.5 years later: stock is just at 375 now But this pullback looks like excellent investment opportunity.

Here’s the Cipla Weekly Chart

As you can see in the chart above – Cipla broke out above 360 to New HIGH in August 2012. Post Breakout and lots of consolidation – stock rallied to 450. But in last few months, stock has pulled back and is now at 100 week ma.
Trading Rule: Breakout that has sustained so long becomes excellent buying opportunity at moving average
One can look to buy Cipla at 100 week ma with closing stop loss of 3% below 100 week ma.

BUY CIPLA AT 375  IN FUT FOR SHORT TERM CLOSING SL  BELOW 360 IN CASH TGT 400-415 SIZE 500

LONG TERM CLINETS TO CAN ADD STOCK IN THE PORTFOLIO BUY AT 375 SL 350 ON CLOSING BASIC TARGET 430 AND BEYOND THAT FOR FRESH ALL TIME HIGHS OF 475- 500 IN MONTHS TO COME

STATE OF MARKET AHEAD OF FOMC AND RBI POLICY TODAY

POSTING SENSEX CHART as its more trustworthy then NIFTY !!

SENSEX 20.5K (Nifty 6100) is the Support I'll be looking for now ..

Two imp Events Coming this week , FED meeting on 18th night and RBI policy on 18th Morning which should decide the fate of our Market ..

Now Technically is 20.5K Gets Broken then We'll Slip Fast to 20.1K and 20K levels on Sensex (  5970-5950 Nifty ) And then Their could be a Fall to 19.5K to 19K levels Very Verly Quicky  (Even in 1-2 days only) That Will be Some Panic Selling & Bears Will have an Upper Hand that time after a Long time..

BANK NIFTY  Supp @ 11.3-11.1K around and once that 11000 mark is broken then We can see a Quick 5-10% crack in Bank Nifty ( A 50 BPS rate Hike on 18th is Perfect Catalyst for the Crackdown ) The 11000 Bank nifty puts Which Are Trading @ 100-80 Can do 700-1000 also If We Get a 50 BPS rate Hike on 18th ...

Lets Now Look Into the Technical Charts :

 

SENSEX WEEKY 

 

BANK NIFTY

Some Short Selling Ideas 

1. A NIFTY HEAVY WEIGHT ONLY TO CLIENTS

2.ANOTHER NIFTY HEAVY WEIGHT ONLY TO CLIENTS

3. BANK BARODA

 

WIPRO MULTI YEAR BREAKOUT ANOTHER TECHM IN MAKING

" WIPRO " MULTI-YEAR BREAKOUT ...CAN MOVE 30-50% Up in Very Short term

Hope you Remember My Famous TECH-M 

Buy Reco  @ 1125 & now its 1725+

 

http://trendzofmarket.blogspot.in/2013/07/techmahindra-blasted-multi-year-break.html 

WIPRO IS NOW ALL SET TO FOLLOW THE PATHS OF TECHMAHINDRA AFTER GIVING  4 YEAR BREAK OUT 

Strongly reco TO BUY Wipro  @ 510-20 levels  for 700 in  few months time

GLAXO PHARMA ANOTHER PICTURE PERFECT TECHINCAL MOVES 30 %

WE CAME OUT ON A DETAILED ANALYSIS AND BUY CALL ON GLAXO PHARMA TO PUR PAID CLIENTS ON NOV AND UPDATED IN BLOG ABOUT A PHARAM STOCK ON NOV 18 TH TO BUY GLAXO PHARMA @ 2397   EXPECTING A SHARP RALLY TODAY ON THE BACK OF NEWS STOCK WAS ON FIRE CLOCKED UPPER CIRCUT HIT 2900  MOVE 600 RS ON NO TIME

THIS WAS OUR MAIL TO OUR CLIENTS ON NOV 18

Glaxo Pharma stock has done nothing in last 2-3 years but it seems that’s about to change. Here’s why





Glaxo Pharma stock created a stiff resistance around 2400 for years. It’s only in May 2013- the stock broke past 2400 and since then has been on consolidation drive. The stock seems to be establishing base around 50 week ma (2293) and 2400 which is very bullish and once stock takes off from here – we are looking at multi year bull market in the stock.
What is a MULTI YEAR BULL MARKET
When stocks breakout from a well established multi year resistance: they run a marathon post breakout for years. Here’s one example: Apollo Hospitals
Apollo Hospitals broke out above 300 in Dec 2009 and then over next 3.5 years: stock tripled despite overall bad market environment. That’s what happens when stock breaks out after many years. They can run on their own.
Glaxo Pharma: Investment worthy
I am not saying Glaxo Pharma will succeed in same way as Apollo Hospitals. It may or it may not but the promise is there for multi year bull market. Remember, we are in a market and there is no certainty of anything. Glaxo Pharma is investment worthy stock and not suitable for trading and short term gains. Having said that – one should look to exit if stock slips below 2190 on closing basis.

THIS WAS THE NEWS WHICH HELPED TO STOCK  MOVE IN A BIG WAY
London-listed GlaxoSmithKline plc announced a voluntary open offer to increase its stake in its publicly-listed pharmaceuticals subsidiary in India, GlaxoSmithKline Pharmaceuticals Limited , from 50.7 percent to up to 75 percent at a price of Rs 3,100 per share.

GSK added that it intends to keep the company listed, which means it will not hike its stake any further after the open offer. Securities regulations in India require a minimum public shareholding of 25 percent for a company to maintain a public listing.

The open offer, in which the parent firm intends to buy 2,06,09,774 shares, or 24.3%, of the company, represents a premium of about 26 percent of the stock's closing price on December 13. “For GSK, this transaction will increase exposure to a strategically important market and for our Indian pharmaceuticals subsidiary’s shareholders we believe it offers a good liquidity opportunity at an attractive premium," David Redfern, Chief Strategy Officer, GSK, said in a statement. “GSK has a proud heritage in India. Today’s announcement is a further demonstration of our long-term commitment to the country having increased our holding in our consumer business earlier this year and more recently committed to a significant manufacturing investment.” HSBC Securities is the manager for this open offer.

 The transaction will be funded through GSK’s existing cash resources, will be earnings neutral for the first year and accretive thereafter and will not impact expectations for the group’s long-term share buyback programme, the parent company said.